|
Dr. Thorsten Siess joined ABIOMED in 2005 upon its acquisition of Impella CardioSystems, AG, which he co-founded in 1998 and has served as Manager of R&D, then Chief Technology Officer. His work in the development and marketing of the Impella 2.5 and 5.0 in Europe led to their CE Mark approval. During his time at the University of Aachen he developed the Impella technology which served as a platform for the entire Impella product portfolio. The products, which allow early intervention through a pencil-sized VAD, are now available in 70 centers in 11 countries. Dr. Siess is leading the effort at ABIOMED to make these products available in the U.S., pending FDA approval. Prior to founding Impella, Dr. Siess served as Scientist in the Biomedical Technology Team at Helmholtz-Institute of Biomedicine at the University of Aachen in Germany. Dr. Siess received a Ph.D. degree as well as his MASc in Mechanical Engineering from the University of Aachen. | 